Current and future medical treatments for menometrorrhagia during the premenopause

References

• Marret H, Fauconnier A, Chabbert-Buffet N, Cravello L, Golfier F, Gondry J, Agostini A, et al.; CNGOF Collège National des Gynécologues et Obstétriciens Français. Clinical practice guidelines on menorrhagia: Management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol 2010;152:133–137.
   PubMed Web of Science ®Google Scholar
• Coulter A, Peto V, Jenkinson C. Quality of life and patient satisfaction following treatment for menorrhagia. Fam Pract 1994;11:394–401.
   PubMed Web of Science ®Google Scholar
• Maybin JA, Critchley HO. Progesterone: A pivotal hormone at menstruation. Ann N Y Acad Sci 2011;1221:88–97.
   PubMed Web of Science ®Google Scholar
• Lockwood CJ. Mechanisms of normal and abnormal endometrial bleeding. Menopause 2011;18:408–411.
   PubMed Web of Science ®Google Scholar
• Shaw RW. Assessment of medical treatments for menorrhagia. Br J Obstet Gynaecol 1994;101 Suppl 11:15–18.
   Google Scholar
• Irvine GA, Cameron IT. Medical management of dysfunctional uterine bleeding. Baillieres Best Pract Res Clin Obstet Gynaecol 1999;13:189–202.
   PubMed Web of Science ®Google Scholar
• Roman H, Loisel C, Puscasiu L, Sentilhes L, Marpeau L. [Management of menometrorrhagia in women with and without pregnancy intention: Hierarchy of therapies]. J Gynecol Obstet Biol Reprod (Paris) 2008;37 Suppl 8:S405–S417.
   Google Scholar
• De Falco M, Pollio F, Pontillo M, Ambrosino E, Busiello A, Carbone IF, Ciociola F, et al. [GnRH agonists and antagonists in the preoperative therapy of uterine fibroids: Literature review]. Minerva Ginecol 2006;58:553–560.
   Google Scholar
• Rein MS. Advances in uterine leiomyoma research: The progesterone hypothesis. Environ Health Perspect 2000;108 Suppl 5:791–793.
   Google Scholar
• Roberts TE, Tsourapas A, Middleton LJ, Champaneria R, Daniels JP, Cooper KG, Bhattacharya S, Barton PM. Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: Cost effectiveness analysis. BMJ 2011;342:d2202.
   PubMed Web of Science ®Google Scholar
• Flynn M, Jamison M, Datta S, Myers E. Health care resource use for uterine fibroid tumors in the United States. Am J Obstet Gynecol 2006;195:955–964.
   PubMed Web of Science ®Google Scholar
• Mote PA, Balleine RL, McGowan EM, Clarke CL. Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. J Clin Endocrinol Metab 1999;84:2963–2971.
   PubMed Web of Science ®Google Scholar
• Li Q, Kannan A, DeMayo FJ, Lydon JP, Cooke PS, Yamagishi H, Srivastava D, et al. The antiproliferative action of progesterone in uterine epithelium is mediated by Hand2. Science 2011;331:912–916.
   Google Scholar
• Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: Mechanisms of action and clinical applications. Hum Reprod Update 2005;11:293–307.
   PubMed Web of Science ®Google Scholar
• Bouchard P, Chabbert-Buffet N, Fauser BCJM. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril 2011;96:1175–1189.
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P; VA2914 Study Group. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: A prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007;92:3582–3589.
   PubMed Web of Science ®Google Scholar
• Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 2007;87:1399–1412.
   PubMed Web of Science ®Google Scholar
• Wilkens J, Chwalisz K, Han C, Walker J, Cameron IT, Ingamells S, Lawrence AC, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 2008;93:4664–4671.
   PubMed Web of Science ®Google Scholar
• Levens ED, Potlog-Nahari C, Armstrong AY, Wesley R, Premkumar A, Blithe DL, Blocker W, Nieman LK. CDB-2914 for uterine leiomyomata treatment: A randomized controlled trial. Obstet Gynecol 2008;111:1129–1136.
   PubMed Web of Science ®Google Scholar
• Nieman LK, Blocker W, Nansel T, Mahoney S, Reynolds J, Blithe D, Wesley R, Armstrong A. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: A randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril 2011;95:767–72.e1.
   Google Scholar
• Xu Q, Takekida S, Ohara N, Chen W, Sitruk-Ware R, Johansson ED, Maruo T. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5′-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab 2005;90:953–961.
   PubMed Web of Science ®Google Scholar
• Xu Q, Ohara N, Chen W, Liu J, Sasaki H, Morikawa A, Sitruk-Ware R, et al. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod 2006;21:2408–2416.
   PubMed Web of Science ®Google Scholar
• Ravet S, Munaut C, Blacher S, Brichant G, Labied S, Beliard A, Chabbert-Buffet N, et al. Persistence of an intact endometrial matrix and vessels structure in women exposed to VA-2914, a selective progesterone receptor modulator. J Clin Endocrinol Metab 2008;93:4525–4531.
   PubMed Web of Science ®Google Scholar
• Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005;12:227–233.
   PubMed Web of Science ®Google Scholar
• Horne FM, Blithe DL. Progesterone receptor modulators and the endometrium: Changes and consequences. Hum Reprod Update 2007;13:567–580.
   PubMed Web of Science ®Google Scholar
• Mutter GL, Bergeron C, Deligdisch L, Ferenczy A, Glant M, Merino M, Williams AR, Blithe DL. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008;21:591–598.
   PubMed Web of Science ®Google Scholar
• Lakha F, Ho PC, Van der Spuy ZM, Dada K, Elton R, Glasier AF, Critchley HO, et al. A novel estrogen-free oral contraceptive pill for women: Multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Reprod 2007;22:2428–2436.
   PubMed Web of Science ®Google Scholar